Clinical and Molecular Correlates of Tumor Aneuploidy in Metastatic Non-small Cell Lung Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2024 Aug 21

PMID 39169079

Authors

Liam F Spurr

Sean P Pitroda

Affiliations

Soon will be listed here.

Abstract

Recent studies have linked elevated tumor aneuploidy to anti-tumor immune suppression and adverse survival following immunotherapy. Herein, we provide supportive evidence for tumor aneuploidy as a biomarker of response to immunotherapy in patients with non-small cell lung cancer (NSCLC). We identify a dose-response relationship between aneuploidy score and patient outcomes. In two independent NSCLC cohorts (n = 659 patients), we demonstrate a novel association between elevated aneuploidy and non-smoking-associated oncogenic driver mutations. Lastly, we report enrichment of TERT amplification and immune-suppressive phenotypes of highly aneuploid NSCLC. Taken together, our findings emphasize a potentially critical role for tumor aneuploidy in guiding immunotherapy treatment strategies.

References

Taylor A, Shih J, Ha G, Gao G, Zhang X, Berger A . Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018; 33(4):676-689.e3. PMC: 6028190. DOI: 10.1016/j.ccell.2018.03.007. View

Shih J, Sarmashghi S, Zhakula-Kostadinova N, Zhang S, Georgis Y, Hoyt S . Cancer aneuploidies are shaped primarily by effects on tumour fitness. Nature. 2023; 619(7971):793-800. PMC: 10529820. DOI: 10.1038/s41586-023-06266-3. View

Vasudevan A, Schukken K, Sausville E, Girish V, Adebambo O, Sheltzer J . Aneuploidy as a promoter and suppressor of malignant growth. Nat Rev Cancer. 2021; 21(2):89-103. DOI: 10.1038/s41568-020-00321-1. View

Ben-David U, Amon A . Context is everything: aneuploidy in cancer. Nat Rev Genet. 2019; 21(1):44-62. DOI: 10.1038/s41576-019-0171-x. View

Davoli T, Uno H, Wooten E, Elledge S . Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017; 355(6322). PMC: 5592794. DOI: 10.1126/science.aaf8399. View

Alessi J, Awad M . Letter to the Editor: Reply to Kus and Aktas. J Thorac Oncol. 2023; 18(8):e84-e85. DOI: 10.1016/j.jtho.2023.05.018. View

Spurr L, Martinez C, Kang W, Chen M, Zha Y, Hseu R . Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022; 3(12):1498-1512. DOI: 10.1038/s43018-022-00467-x. View

Spurr L, Weichselbaum R, Pitroda S . Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022; 54(12):1782-1785. DOI: 10.1038/s41588-022-01235-4. View

Liu L, Bai X, Wang J, Tang X, Wu D, Du S . Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. Clin Cancer Res. 2019; 25(24):7413-7423. DOI: 10.1158/1078-0432.CCR-19-0558. View

10.

Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51(2):202-206. PMC: 6365097. DOI: 10.1038/s41588-018-0312-8. View

11.

Popat S, Liu S, Scheuer N, Gupta A, Hsu G, Ramagopalan S . Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2022; 5(5):e2214046. PMC: 9133943. DOI: 10.1001/jamanetworkopen.2022.14046. View

12.

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

13.

Girish V, Lakhani A, Thompson S, Scaduto C, Brown L, Hagenson R . Oncogene-like addiction to aneuploidy in human cancers. Science. 2023; 381(6660):eadg4521. PMC: 10753973. DOI: 10.1126/science.adg4521. View

14.

Spurr L, Pitroda S . Exploiting tumor aneuploidy as a biomarker and therapeutic target in patients treated with immune checkpoint blockade. NPJ Precis Oncol. 2024; 8(1):1. PMC: 10761678. DOI: 10.1038/s41698-023-00492-8. View

15.

Ravi A, Hellmann M, Arniella M, Holton M, Freeman S, Naranbhai V . Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023; 55(5):807-819. PMC: 10181943. DOI: 10.1038/s41588-023-01355-5. View

16.

Spurr L, Alomran N, Bousounis P, Reece-Stremtan D, Prashant N, Liu H . ReQTL: identifying correlations between expressed SNVs and gene expression using RNA-sequencing data. Bioinformatics. 2019; 36(5):1351-1359. PMC: 7058180. DOI: 10.1093/bioinformatics/btz750. View

17.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

18.

Bhattacharya S, Dunn P, Thomas C, Smith B, Schaefer H, Chen J . ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018; 5:180015. PMC: 5827693. DOI: 10.1038/sdata.2018.15. View

19.

Fares C, Van Allen E, Drake C, Allison J, Hu-Lieskovan S . Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. Am Soc Clin Oncol Educ Book. 2019; 39:147-164. DOI: 10.1200/EDBK_240837. View

20.

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View